MSD Korea targets antidiabetic market

Industry watchers expect the domestic antidiabetic market is about to heat up, as MSD Korea's sitagliptin phosphate (Januvia), an oral diabetes medication in a new class of drugs known as DPP-4 inhibitors, will soon join the market.

Handok Pharm and GlaxoSmithKline are engaged in cutthroat competition to take the top place in Korea's antidiabetic market with Amaryl and Avandia.

Up until...